99mTc labeled VIP analog:: evaluation for imaging colorectal cancer
99mTc labeled VIP analog:: evaluation for imaging colorectal cancer
复制标题
DOI:
10.1016/s0969-8051(01)00205-0
复制
发表时间:
2001-05-01
影响因子:
3.1
通讯作者:
Marcus, CS
中科院分区:
文献类型:
--
作者:
Rao, PS;Thakur, ML;Marcus, CS
Early and reliable diagnosis of colorectal cancer continues to be demanding and challenging. Colorectal cancer cells express Vasoactive Intestinal Peptide (VIP) receptors in high density. We have prepared a VIP analog (TP3654), labeled it with Tc-99m, and evaluated it in experimental animals as an agent for imaging colorectal cancer. The tissue distribution of Tc-99m-TP3654 has been compared with that of In-111-DTPA-Octreotide and Tc-99m-anti-CEA scan in nude mice bearing human colorectal cancer LS174T. Finally, pharmacokinetic and tissue distribution studies of Tc-99m-TP3654 have been performed in four normal human volunteers. Data suggest that Tc-99m-TP3654 can be prepared efficiently without loss of its receptor specificity and biological activity. Although the 24 hr tumor uptake of Tc-99m-TP3654 in the animal model used was modest (0.21 +/- 0.07% I.D./g), the tissue distribution profile was more favorable than that of In-111-DTPA-Octreotide or Tc-99m-anti-CEA scan. Human studies indicated that Tc-99m-TP3654 had no adverse effect in any subject. Within 24 hours, approximately 70% of the injected dose cleared through the kidneys, and approximately 20% through the hepatobiliary system. In these non-fasting Volunteers hepatobiliary clearance was slow and in cancer patients tumor uptake was rapid. Data suggest that Tc-99m-TP3654 is a promising agent for imaging colorectal cancer. (C) 2001 Elsevier Science Inc. All rights reserved.